Serum reference value of two potential doping candidates—myostatin and insulin-like growth factor-I in the healthy young male by Der-Sheng Han et al.
RESEARCH ARTICLE Open Access
Serum reference value of two potential
doping candidates—myostatin and
insulin-like growth factor-I in the healthy
young male
Der-Sheng Han1,2,3,5, Chi-Huang Huang3, Ssu-Yuan Chen4,8* and Wei-Shiung Yang5,6,7*
Abstract
Background: Myostatin negatively regulates muscle growth, and its inhibition by suitable proteins can increase
muscle bulk and exercise performance. However, the reference values of serum myostatin in athletes performing
strength training are still lacking.
Methods: A cross-sectional study recruiting28 male collegiate athletes performing strength training and 29 age-
matched normal controls was conducted.
The serum concentration of myostatin and insulin-like growth factor 1 (IGF-1), grip strength, and body composition
were the main outcome measures. We used regression models to analyze the correlation between serum markers
and the physiological parameters. The athlete group had greater height, weight, body mass index (BMI), fat mass
percentage, fat-free mass, muscle mass, waist girth, grip strength, and estimated daily energy expenditure.
Results: The IGF-1 concentration was higher in the athlete group (324 ± 80 vs. 263 ± 134 ng/ml), but the myostatin
levels did not differ (12.1 ± 3.7 vs. 12.4 ± 3.5 ng/ml). The reference value for IGF-1 among the healthy young males
was 293 ± 114 ng/ml, correlated with age and height; the value for myostatin was 12.3 ± 3.6 ng/ml, correlated
negatively with BMI, fat mass percentage, and waist girth after adjustment for age.
Conclusion: Myostatin level is negatively related to fat percentage, and serum IGF-1 is positively related to height.
The reference values could provide a basis for future doping-related study.
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Background
As a member of the transforming growth factor β
superfamily, myostatin is a negative regulator of muscu-
lar growth and differentiation. Myostatin knock-out
mice have three times more muscle mass than their
wild-type counterparts [1]. Better functional perform-
ance is also observed without noticeable physiological
compromise in these animals. On the other hand, nude
mice over-expressing myostatin showed a cachectic
phenotype with both skeletal muscle and adipose tissue
atrophy [2]. Myostatin is translated into a 310-amino
acid peptide, and cleaved as N terminal propeptide and
C terminal active peptide. It is then circulated in the
blood as an endocrine hormone [2]. The N-terminal
propeptide is a potent inhibitor for myostatin. In a hu-
man study, a male baby born to a professional athlete
mother in Germany was found to have a bulky muscle
mass and loss-of-function myostatin mutation [3]. The
serum myostatin peptide level was as low as undetect-
able in this male baby. It is reasonable to hypothesize
that inhibiting myostatin can increase muscle mass and
strength, and the sports performance of athletes. Another
study revealing that the serum myostatin propeptide
concentration in a bodybuilder was significantly higher
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than that in an untrained volunteer supports this hy-
pothesis [4]. Strength training, a mode of exercise that
can increase muscle mass, can modulate myostatin.
Strength training inhibits intramuscular myostatin
mRNA and protein expression in rats [5]. In a human
study, similar findings were reported by Roth et al. that
muscular myostatin mRNA level decreased 37% in
healthy volunteers after a 9-week course of heavy uni-
lateral knee extension strength training [6]. In addition,
Walker et al. claimed that the serum myostatin peptide
concentration, analyzed with Western blot, decreased
20% in a healthy male volunteer after a 10-week whole
body strength training course [7].
Insulin-like growth factor-1 (IGF-1), a downstream mol-
ecule of the growth hormone (GH), increases protein syn-
thesis in skeletal muscle. IGF-1 transgenic mice have
accelerated skeletal muscle regeneration. The hypertrophic
effects of IGF-I infusion on muscle are well documented in
animal models and muscle cell culture systems. [8, 9]
IGF-1 expression increased in a rat model of cardio-
myocyte hypertrophy and in healthy volunteers doing
strengthening exercises [10]. Using the C2C12 myotube
model, a dose-dependent reduction in myostatin expres-
sion was observed on exposure to GH; this action was
reversed by the GH antagonist pegvisomant [11]. We pre-
viously proposed that myostatin and IGF-1 could serve as
a brake and accelerator mechanism for regulating muscle
mass or function [12]. Based on this accelerator-brake
model, we hypothesized that both IGF-1 and myostatin
may correlate with lean or fat-free mass.
Due to their ability to modulate muscle mass and
function, myostatin and IGF-1 genes and their protein
products might be a target for doping [13]. Myostatin-
inhibiting antibody and muscle-specific expression of
IGF-I were shown to increase the muscle mass and func-
tion of mdx mice, an animal model of Duchenne muscu-
lar dystrophy [14, 15]. It is reasonable to expect
improved muscle function after injection of exogenous
IGF-1, myostatin propeptide, or myostatin neutralizing
antibody, which will change their serum concentrations.
However, we still do not have their reference value in
the general population or in the athlete. Therefore, we
conducted a cross-sectional study to investigate the refer-
ence values of serum myostatin and IGF-1 concentrations
in male student athletes and untrained counterparts, and
secondarily to determine whether relationships with body




Twenty-eight male athletes from sports-related depart-
ments in the National Taiwan Sports University were
recruited after obtaining their written informed con-
sent. Their training program consisted of strength
training for at least one hour per day and five times per
week. Collegiate athletes were from the weight-lifting
team (n = 10) and the basketball team (n = 18). Another
29 age-matched college students from non-sports-related
departments were recruited as untrained controls for this
study (Fig. 1). The Research Ethics Committee of National
Taiwan University Hospital conforming to the Declaration
of Helsinki of the World Medical Association approved
the study.
Ten milliliters of whole blood sample was collected
through venipuncture at antecubital vein. The serum
was isolated and stored in a -20 °C refrigerator for bio-
chemical analysis. The maximal grip strength of the
Fig. 1 Study design
Han et al. Journal of the International Society of Sports Nutrition  (2017) 14:2 Page 2 of 7
dominant hand of each individual in standardized
arm and hand positions was measured with an analog
isometric dynamometer (Baseline® hydraulic hand
dynamometer, Fabrication Enterprises Inc., Irvington,
NY, USA) -the highest value of three attempts was
used for analysis [16]. Height was measured to the
nearest 0.1 cm and weight to the nearest 0.1 kg on
an electronic scale. Waist girth was measured with a
soft tape midway between the last rib and the iliac
crest in a standing position. Body mass index (BMI)
was calculated as weight in kg divided by the square of the
height in meters.
Body composition
The parameters of body composition, resistance, and im-
pedance were obtained with a bio-impedance analyzer
(Bio Scan 920, Maltron, UK) using the manufacturer’s
suggested protocol. In brief, two injector electrodes
were placed on the dorsal surface of the foot and wrist
at distal metatarsals and metacarpals. Two detector
electrodes were placed between the styloid process of
the radius and ulna, and between the medial and lateral
malleolus. During the measurement, subjects remained
in a supine position with feet apart and hands at their
sides. A low alternating current (500 μA, 50 kHz) was
passed through the body to determine the fat-free mass,
fat mass (FM), and muscle mass by the equation default
in the analyzer. Percentage of body fat was calculated
manually as FM/body weight × 100%. The cross-validation
of this machine determining body fat was performed
previously [17].
Physical activity recall scale
The self-administered Physical Activity Recall Scale (PAR)
was employed to estimate daily energy expenditure [18].
The PAR included questions about time spent sleeping
and in performing moderate, hard, and very hard intensity
activities each day, both weekday and weekend. The time
frame measured was the 7 days previous to the interview.
Total daily energy expenditure was estimated by assigning
to each activity category standard values of intensity
expressed as multiples of metabolic equivalents (METs).
One MET was defined as the resting metabolic rate, which
was approximately equal to 1 kcal/kg/h. Activities were
assigned as: sleep (1.0 MET), light (1.5 MET), moderate
(4.0 MET), hard (6.0 MET), and very hard (10.0 MET). By
multiplying the METs and reported time spent in each ac-
tivity, summing all intensities, and multiplying body
weight, we could obtain a summary score for daily energy
expenditure in kcal [19]. Hours spent in light activities
were calculated by subtracting from 168 h the sum of the
time spent in the other reported activity categories.
Biochemistry analysis
Serum myostatin level was measured with an ELISA kit
from Immunodiagnostik (Bensheim, Germany). The test
employed a polyclonal antibody against a full-length
myostatin peptide with a competitive immunoassay
technique. The sensitivity of myostatin ELISA is
270 pg/ml, and the intra- and inter-assay variability are
less than 10 and 15% [20]. Serum IGF-1 was measured
with Mediagnost’s ELISA kit (Reutlingen, Germany).
The sensitivity, intra- and inter-assay variabilities of the
IGF-1 ELISA kit are 90 pg/ml, 6.7%, and 6.8%, respectively.
The absorption of each well was read using a VersaMAX
tunable microplate reader (Molecular Devices, Sunnyvale,
CA, USA) at 450 nm against 620 nm as a reference.
Statistical analysis
The test of means between the normal control and the
athlete group was performed with Student’s t test. A
Wilcoxon rank-sum test was employed to compare the
means between the basketball and the weight-lifting
team. Pearson’s correlation analysis was used between
the serum markers and other variables. The linear re-
gression model was used to analyze the association after
adjustment between serum markers and body compos-
ition and physical activity. Then, the stepwise linear re-
gression was used to find the determinants of myostatin
and IGF-1. Statistical analysis was performed with SPSS®
11.5 (SPSS Inc. Chicago, Illinois, USA) with significance
levels set at 0.05.
Results
Twenty-eight athletes and 29 age-matched normal con-
trols were recruited. There was no difference in age be-
tween the athlete and control groups (20.5 ± 1.2 vs. 21.2
± 1.6 years). The athlete group had greater height,
weight, BMI, FM percentage, fat-free mass, muscle mass,
waist girth, grip strength, and estimated daily energy ex-
penditure. As to the biomarker level, the serum IGF-1
concentration was higher in the athlete group; however,
the serum myostatin levels did not differ (Table 1). We
then pooled the cohort and found the reference levels of
myostatin and IGF-1 were 12.3 ± 3.6 ng/ml and 293 ±
114 ng/ml, respectively, in the young healthy males.
Since the athlete group was composed of two sports
teams, basketball and weight-lifting, we compared the
difference between these two teams. The basketball team
had greater height, fat-free mass and muscle mass, and
less grip strength than the weight-lifting team. The two
serum markers did not differ between these two sports
teams, or between the control and these two teams
(Table 1).
We then pooled all samples and analyzed the correl-
ation between serum myostatin and other parameters.
Myostatin correlated negatively with age and fat mass
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percentage. It was not correlated with muscle mass, grip
strength, and daily energy expenditure. IGF-1 correlated
negatively with age, and positively with height, fat-free
mass, and estimated daily energy expenditure (Table 2).
Myostatin was positively correlated to IGF-1, but with-
out statistical significance. We further performed sub-
group analysis to see if the correlation of serum markers
and other parameters was different in the athlete group
and control group, but no significant difference was
found (data not shown).
In order to adjust the impact of age, we employed the
linear regression model to analyze the correlation after ad-
justment for age between biomarkers and body compos-
ition and grip strength. The level of myostatin was
significantly negatively correlated with BMI, fat mass per-
centage, and waist girth. The IGF-1 level was correlated
only with height after adjustment for age (Table 3). Based
on the analysis of correlation, we then performed stepwise
linear regression to find the determinants of myostatin
and IGF-1. First, we took myostatin as a dependent vari-
able, and age, BMI, fat mass percentage and waist girth as
independent variables, and found that age (β = -0.897 ±
0.295, p = 0.004) and BMI (β = -0.268 ± 0.110, p = 0.018)
were independently related to myostatin. Second, taking
IGF-1 as a dependent variable, age, height, BMI, fat-free
mass and estimated daily energy expenditure as inde-
pendent variables, we found that age (β = -34.27 ± 8.89,
p <0.001) and height (β = 360.5 ± 167.0, p = 0.035) were
independently related to IGF-1.
Discussion
In this study, we established the reference value of myos-
tatin and IGF-1 and found their relationships with body
composition from a cross-sectional cohort. We demon-
strated that the reference value of the myostatin serum
concentration in healthy young males was 12.3 ± 3.6 ng/
ml, which was correlated negatively with age. After adjust-
ment for age, the reference value was negatively correlated
with BMI, fat mass percentage, and waist girth. The
Table 1 The demographic data and baseline biomarker concentrations of college students and athletes performing strength
training; data are expressed as Mean (SD)
Control Athlete P value*
All athletes Basketball Weight lifting
N 29 28 18 10
Age (year) 21.2 (1.6) 20.5 (1.2) 20.6 (1.3) 20.6 (1.2) 0.083
Height (cm) 174 (6) 181 (8) 185 (7)** 173 (4) 0.002
Weight (kg) 69.0 (8.9) 88.3 (15.2) 90.0 (15.4) 85.3 (15.2) <0.001
BMI (kg/m2) 22.5 (2.4) 26.9 (4.1) 26.0 (3.5) 28.4 (4.8) <0.001
Fat mass (%) 13.1 (4.4) 18.2 (9.1) 16.6 (8.1) 21.2 (10.4) 0.011
Fat-free mass (kg) 59.7 (6.1) 71.2 (7.7) 74.1 (7.2)** 65.9 (5.6) <0.001
Muscle mass (kg) 27.8 (3.5) 34.3 (4.3) 35.7 (4.2)** 31.8 (3.4) <0.001
Waist girth (cm) 80.2 (7.2) 89.9 (10.8) 90.0 (10.3) 89.5 (12.0) <0.001
Grip strength (kg) 42.9 (4.4) 48.5 (6.1) 46.5 (5.6)** 52.1 (5.4) <0.001
Myostatin (ng/mL) 12.4 (3.5) 12.1 (3.7) 12.6 (3.9) 11.2 (3.3) 0.740
IGF-1 (ng/ml) 263 (134) 324 (80) 318 (82) 334 (80) 0.043
Estimated daily energy expenditure (kcal/day) 3059 (1123) 4152 (813) 4216 (794) 4036 (877) <0.001
*denotes p value of t-test between control and all athletes
**denotes significance of Wilcoxon rank-sums test between basketball and weight-lifting teams
Table 2 Correlation analysis between myostatin and IGF-1 and
other parameters. The data are expressed as Pearson’s correl-
ation coefficient (p value)
Myostatin (ng/ml) IGF-1 (ng/ml)
N 57 57
Groupa −0.045 (0.740) 0.269 (0.043)*
Age (year) −0.335 (0.011)* −0.470 (<0.001)**
Height (cm) 0.146 (0.280) 0.287 (0.031)*
Weight (kg) −0.133 (0.324) 0.226 (0.091)
BMI (kg/m2) −0.248 (0.063) 0.125 (0.354)
Fat mass (%) −0.304 (0.022)* 0.036 (0.789)
Fat-free mass (kg) 0.040 (0.768) 0.303 (0.022)*
Muscle mass (kg) 0.024 (0.857) 0.246 (0.065)
Waist girth (cm) −0.248 (0.063) 0.040 (0.767)
Grip strength (kg) 0.029 (0.832) 0.246 (0.065)
Estimated daily energy
expenditure (kcal/day)
−0.067 (0.620) 0.380 (0.004)**
Myostatin (ng/ml) - 0.174 (0.195)
IGF-1 (ng/ml) 0.174 (0.195) -
*: p <0.05
**: p <0.01
a: Control group is 0; athlete group is 1
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reference value for IGF-1 was 293 ± 114 ng/ml, which was
correlated with age negatively and height positively.
Because myostatin is thought to be a myokine—a
muscle secreted cytokine [12], its serum levels have been
reported in clinical conditions related to muscle growth
rather than in the healthy condition. However, it is diffi-
cult to compare the serum myostatin level with previous
studies, since the reported levels varied greatly due to
the use of different ELISA kits. Using the same ELISA
kit as in our study, Ju and Chen revealed that the serum
myostatin level was higher in patients with chronic ob-
structive pulmonary disease (COPD) than in the healthy
control (11.85 ± 4.01 vs. 7.46 ± 2.21 ng/ml) [21]. The
myostatin level of COPD patients was correlated with
BMI negatively and with the serum tumor necrosis fac-
tor α level positively. Using the same ELISA kit, Zamora
et al. found the mean myostatin serum concentration
was 12.3 ng/ml in chronic heart failure patients aged
72.3 years on average [22]. No correlation was found be-
tween serum myostatin and parameters of disease sever-
ity and prognosis. Wintgens et al. demonstrated that the
myostatin level was elevated in decompensated congest-
ive heart failure patients compared with the normal con-
trol (49 vs. 32 ng/ml). The level decreased to the normal
level after recompensating therapy [20]. Lakshman et al.
measured serum myostatin level with a monoclonal
antibody-based sandwich ELISA. They reported the
myostatin level to be 8.0 ± 2.3 ng/ml in healthy young
men with an average age of 26.5 years [23]. The level in
older men with age of 66.4 ± 4.7 years dropped significantly
to 7.0 ± 2.5 ng/ml. In summary, the serum concentration
of myostatin seems to range from 7 to 32 ng/ml in the gen-
eral population.
Myostatin affects the growth of both muscle and lipid.
Our study, recruiting healthy young male subjects, found
myostatin was negatively related to BMI, fat mass per-
centage, and waist girth after adjustment for age. Feld-
man et al. reported that myostatin transgenic mice had
immature adipogenesis resulting in lower body weight,
serum triglycerides (TG), and fasting plasma glucose
[24]. Two other studies also concluded that administra-
tion of recombinant myostatin protein to 3 T3-L1 pre-
adipocytes or human mesenchymal stem cells blocked
their adipogenesis [25]. In a human study, a 6-month
lifestyle intervention reduced the body weight of obese
children aged between 6 – 16 years. At the same time,
serum myostatin elevation and a decrease in fat mass
and BMI were also observed [26]. Furthermore, in a gen-
etic study recruiting 500 non-diabetic Asian Indians in
north India, subjects with myostatin polymorphism
A55T were reported to have a higher body fat percent-
age, fat mass, and truncal adiposity [27]. We have ob-
served that a lower serum myostatin concentration is
related to metabolic syndrome, central obesity, low high-
density lipoprotein cholesterol, and high TG among 246
diabetic patients after adjusting age and gender [28].
Thus, when we determine the normal value of serum
myostatin, it is prudent to take fat-related parameters
into consideration.
Myostatin exerts its main effect through autocrine/
paracrine mode, and excess myostatin peptide will spill-
over into the circulation. Like the other members of the
TGF-β superfamily, myostatin is regulated by complex
interactions with many proteins in extracellular matrix
[29]. Therefore, intracellular mRNA and secretion in iso-
lated muscle tissues may not faithfully reflect its circulat-
ing levels. Matsakas et al reported that rat myostatin
mRNA expression reduced after swimming training for
4 weeks, not after acute bout of exercise; however, no
myostatin protein change was detected [30]. Myostatin is
also expressed in the cardiac muscle, and this may con-
tribute to the serum myostatin level [31]. Myostatin
mRNA expression is increased after infarction and exer-
cise in the cardiac muscle, but remain unchanged in the
canine model of dilated cardiomyopathy and chronic
heart failure [22, 32]. Myostatin may be a mediator of
cardiac development; however, the exact mechanism still
need to be elucidated [33].
We previously proposed an “accelerator-brake model”
to illustrate the role of myostatin in regulating muscle
growth [12]. Myostatin served as a negative feedback mol-
ecule during the process of muscular growth or regener-
ation and limited the skeletal muscle mass [10]. In this
model, myostatin is activated only when muscle is growing
or regenerating. Our athletes performing strength training
Table 3 Regression coefficients β from multiple linear regression
models for serum myostatin and IGF-1 after adjustment for age
Myostatin (ng/ml) IGF-1 (ng/ml)
Groupa −0.918 ± 0.927 (0.326) 38.3 ± 27.4 (0.169)
Height (cm) 0.051 ± 0.058 (0.377) 3.503 ± 1.673 (0.041)*
Weight (kg) −0.042 ± 0.029 (0.149) 1.169 ± 0.869 (0.184)
BMI (kg/m2) −0.269 ± 0.111 (0.018)* 1.797 ± 3.476 (0.607)
Fat mass (%) −0.141 ± 0.058 (0.018)* 0.695 ± 1.824 (0.705)
Fat-free mass (kg) −0.014 ± 0.052 (0.789) 2.673 ± 1.524 (0.085)
Muscle mass (kg) −0.033 ± 0.092 (0.723) 3.502 ± 2.717 (0.203)
Waist girth (cm) −0.085 ± 0.043 (0.050)* 0.480 ± 1.333 (0.720)




−0.001 ± 0.000 (0.125) 0.025 ± 0.013 (0.051)
IGF-1 (ng/ml) 0.001 ± 0.005 (0.883) -
myostatin (ng/ml) - 0.600 ± 4.072 (0.883)
Data are expressed as β ± standard error (p value)
*: p <0.05
a: Control group is 0; athlete group is 1
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had significantly greater muscle mass, BMI, grip strength,
and daily energy expenditure than their untrained coun-
terparts. However, the serum myostatin level of the two
groups was not significantly different. The main problem
might be the timing of blood sampling after exercise train-
ing. In another study, the acute response to a single bout
of isometric exercise in rats was a rapid increase in myos-
tatin mRNA levels 30 min to 6 h post-exercise, and a
return to baseline levels 24 h post-exercise [34]. The ath-
lete’s body composition is at a steady state, so there is no
difference in myostatin concentration. Future longitudinal
study to observe the dynamic change of muscle mass after
strength training may prove the role of myostatin in decel-
erating muscle growth.
Age is a determining factor of serum myostatin and
IGF-1. Lakshman et al reported lower myostatin level in
the elderly population aged 66.4 ± 4.7 years [23], which
could be explained by “accelerator-brake model”. The
negative relation between IGF-1 and age was also well
established [35]. Since different age groups have different
muscle mass, it is desirable to establish an age-specific
norm for the level of these biomarkers. However, the age
range of our subjects is too narrow to establish such a
norm, so we tried to show their relationship with linear
regression model.
IGF-1, a downstream molecule of growth hormone, is
a serum protein with insulin-like metabolic activities
and growth controlling ability. IGF-1 expression acti-
vates muscular satellite cells and counteracts muscle
function decline in the mouse model of muscular dys-
trophy [14]. GH or IGF-1 has been taken by athletes for
its anabolic effect to enhance sports performance [36].
Since the concentration of GH is highly variable due to
its pulsatile secretion pattern, IGF-1 is suggested as a
good indirect surrogate for the GH/IGF-1 axis in the
GH-2004 Project. An elevated serum IGF-1 level indi-
cated sustained activation of the GH-IGF-1 axis. The re-
ported normal value of IGF-1 is 297 ± 10 ng/ml, and is
related to gender, age, nutrition status, and GH adminis-
tration [35]. In our study, the serum IGF-1 level was
293 ± 114 ng/ml, which was comparable to previous
published reports. Future evaluations of serum IGF-1
levels in other sports are crucial for application in anti-
doping.
There are some limitations in this study. First, the
sample size was small, so the statistical power was lim-
ited. Besides, measurement errors in self-reported phys-
ical activity levels might interfere with regression
analysis. Although PAR is accurate in estimating energy
expenditure compared with other physical activity ques-
tionnaires [37], subjectively perceived exercise intensity
may vary between individuals. Furthermore, the MET
value assigned to each intensity level of physical activity
may differ in respondents having different BMI [38]. In
addition, since the reference value is only for male ath-
lete in certain sports, further validation in other sports is
needed for actual implementation. Finally, because no
commercial kit was available, we cannot measure the
concentration of the pro-peptide, which inactivates
myostatin by binding on it [4].
Conclusions
In conclusion, the reference values of serum myostatin
and IGF-1 levels were 12.3 ± 3.6 ng/ml and 293 ±
114 ng/ml, respectively, in the young healthy males. The
serum myostatin level was negatively related to body fat
percentage; and serum IGF-1 was positively related to
height after adjustment for age. It is necessary to detect
serum myostatin together with other biomarkers, such
as IGF-1, follistatin, and propeptide. Measurement of
myostatin alone would not be sufficient. The reference
values can provide a basis for future study, especially in
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